APA (7th ed.) Citation

RE, P., D, T., M, G., JS, L., S, F., D, J., . . . B, C. (2020). Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. Alimentary pharmacology & therapeutics, 52(8), 1422. https://doi.org/10.1111/apt.16063

Chicago Style (17th ed.) Citation

RE, Prentice, Tjandra D, Garg M, Lubel JS, Fourlanos S, Johnson D, Al-Ani A, and Christensen B. "Letter: ACE2, IBD and COVID-19-why IBD Patients May Be at Reduced Risk of COVID-19." Alimentary Pharmacology & Therapeutics 52, no. 8 (2020): 1422. https://doi.org/10.1111/apt.16063.

MLA (9th ed.) Citation

RE, Prentice, et al. "Letter: ACE2, IBD and COVID-19-why IBD Patients May Be at Reduced Risk of COVID-19." Alimentary Pharmacology & Therapeutics, vol. 52, no. 8, 2020, p. 1422, https://doi.org/10.1111/apt.16063.